New PROTECT III Data Demonstrates Impella® Reduces MACCE at Primary Endpoint

October 15, 2019

Jeffrey J. Popma, MD, presents new data from ongoing FDA post-approval study for PROTECT II randomized control trial.

 

Subscribe or join the conversation by following us on Twitter: @ProtectedPCI

NPS-421


To learn more about the Impella® platform of heart pumps, including important risk and safety information associated with the use of the devices, please visit: www.protectedpci.com/indications-use-safety-information/

Subscribe to the Digital Community

Receive weekly updates including case review videos, tips and tricks, specialists opinions, and resources and downloads regarding Protected PCI and Cardiogenic Shock.

Subscribe to the Digital Community

Receive weekly updates including case review videos, tips and tricks, specialists opinions, and resources and downloads regarding Protected PCI and Cardiogenic Shock.